Drug intelligence / Profile preview

Q11

Development stage
Preclinical
Lead developer
Duke University
Modality
Nanoparticles → Drug Delivery Systems, Peptides
Administration
Subcutaneous, Intramuscular
01

Overview

Q11 is a synthetic, 11-amino acid self-assembling peptide with the sequence Ac-QQKFQFQFEQQ-NH2. It is a prominent biomaterial platform used in the development of subunit vaccines and injectable scaffolds for tissue engineering. Under physiological conditions, Q11 monomers spontaneously organize into stable, non-cytotoxic nanofibers with a beta-sheet architecture. In vaccine applications, antigenic epitopes are typically synthesized as a continuous sequence with the Q11 peptide, allowing for the multivalent display of antigens on the nanofiber surface. This high-density presentation, coupled with Q11's intrinsic ability to act as a self-adjuvant by activating the innate immune system (specifically the NLRP3 inflammasome), significantly enhances the immunogenicity of attached antigens, eliciting robust humoral and cellular immune responses without the need for supplemental inflammatory adjuvants.

Other names
Q11 peptideQ-11 peptideQ 11 peptideQ11 self-assembling peptideQ-11 self-assembling peptideQ 11 self-assembling peptideQ11 nanofibersQ-11 nanofibersQ 11 nanofibers
02

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on Q11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q11.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call